Natera announced that it has appointed Solomon Moshkevich as CEO, effective immediately. Separately, the company disclosed it made a $30 million acquisition on Nov. 2.
Former CEO Steve Chapman has stepped down and resigned from the board but will stay on as a consultant “for an extended period of time,” the company said in a Nov. 5 statement.
Moshkevich has been with Natera for 15 years and was most recently president of clinical diagnostics. He will also join the company’s board of directors.
“Solomon has been deeply involved with every major decision the company has made, and has my full support,” Chapman said in a statement.
In a Nov. 5 filing with the US Securities and Exchange Commission, Natera noted that on Nov. 2 it acquired “one of its strategic partners” for up to $30.0 million, including $5.0 million in performance milestones.
The announcements came as Natera reported revenue growth of 34 percent year over year in the third quarter, driven by solid growth in oncology testing volume, and raised its full-year revenue outlook by $140 million at the midpoint.
Total Q3 revenue was $794.0 million, up from $592.2 million a year ago. The Austin, Texas-based cell-free DNA-based testing company processed just under 1.1 million tests in the quarter, up 22 percent from 893,600 a year ago. Oncology test volume was approximately 339,500, up 61 percent from roughly 211,000 in Q3 2025.
Product revenue was $789.9 million, up from $590.2 million in the year-ago period. Licensing and other revenue doubled year over year to $4.0 million.
Natera’s net loss for the quarter was $59.9 million, or $0.42 loss per share, compared with a net loss of $87.5 million, or $0.64 per share, in Q3 2025, missing the consensus Wall Street estimate of $0.27 loss per share.
R&D expense was $242.4 million, up 40 percent from $173.4 million a year ago, attributable to headcount growth and higher clinical trial costs. SG&A expense was $333.7 million, up 8 percent from $308.5 million.
Natera ended the quarter with $1.10 billion in cash, cash equivalents, and restricted cash.
The company raised its full-year revenue outlook by $140 million at the midpoint. For the full year, Natera now expects revenue of $3.01 billion to $3.04 billion, up from prior guidance of $2.85 billion to $2.91 billion.
Moshkevich will earn a base salary of $900,000 and is eligible for an annual cash bonus targeted at 110 percent of base salary. As part of his promotion, he received a one-time grant of restricted stock units valued at $1.75 million, vesting over four years. His 2027 annual equity award is targeted at $10.5 million, split evenly between performance-based and time-based restricted stock units.
Chapman’s consulting agreement includes a $1.0 million lump sum payable within 10 days, a target 2026 annual bonus of $1.5 million, and 92,933 restricted stock units that will vest in one year.